Black Diamond Therapeutics (NASDAQ:BDTX – Get Rating) and Novavax (NASDAQ:NVAX – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.
Institutional & Insider Ownership
70.4% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 42.6% of Novavax shares are owned by institutional investors. 6.5% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Get Black Diamond Therapeutics alerts:Analyst Ratings
This is a breakdown of recent recommendations and price targets for Black Diamond Therapeutics and Novavax, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Diamond Therapeutics | 0 | 3 | 0 | 0 | 2.00 |
| Novavax | 2 | 0 | 5 | 0 | 2.43 |
Volatility and Risk
Black Diamond Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Novavax has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500.
Earnings & Valuation
This table compares Black Diamond Therapeutics and Novavax's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Black Diamond Therapeutics | N/A | N/A | -$125.60 million | ($3.01) | -0.56 |
| Novavax | $1.15 billion | 1.24 | -$1.74 billion | ($19.46) | -0.94 |
Black Diamond Therapeutics has higher earnings, but lower revenue than Novavax. Novavax is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Black Diamond Therapeutics and Novavax's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Diamond Therapeutics | N/A | -59.14% | -46.54% |
| Novavax | -114.32% | -572.54% | -55.69% |
Summary
Black Diamond Therapeutics beats Novavax on 8 of the 13 factors compared between the two stocks.
About Black Diamond Therapeutics
(Get Rating)
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
About Novavax
(Get Rating)
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.